Completed PHASE2 INTERVENTIONAL 1-arm NCT00927563

Tolcapone Treatment of Pathological Gambling

Tolcapone Treatment of Pathological Gambling: An Open-Label Study

Sponsor: University of Chicago

Interventions Tolcapone

Updated 8 times since 2017 Last updated: Feb 21, 2023 Started: Jun 30, 2009 Primary completion: May 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00927563, this PHASE2 trial focuses on Pathological Gambling and remains completed. Sponsored by University of Chicago, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2021 — Mar 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States